Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

Core Insights - Myriad Genetics and Ultima Genomics have announced a collaboration to utilize Ultima's UG 100™ sequencing platform and ppmSeq™ technology to enhance Myriad's clinical testing capabilities [1][2][3] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [4] - Ultima Genomics aims to revolutionize genomic sequencing by providing low-cost, high-throughput sequencing solutions that can scale beyond conventional technologies [5] Technological Advancements - The UG 100 platform is expected to provide low-cost and low-error sequencing, which will benefit Myriad's emerging products, particularly the Precise Molecular Residual Disease (MRD) test and the FirstGene Multiple Prenatal Screen [2][3] - Myriad's Precise MRD test will utilize whole-genome sequencing to identify tumor-specific variants, enhancing personalized tracking for cancer patients [2] - The FirstGene Multiple Prenatal Screen will streamline multiple prenatal tests into a single sequencing workflow, requiring deep and accurate sequencing capabilities [2] Strategic Goals - Myriad's collaboration with Ultima is aimed at making cutting-edge genetic testing more accessible and affordable, with the UG 100 potentially lowering costs and improving quality for their tests [3] - The partnership is expected to facilitate the exploration of new product areas that may have been previously challenging due to high sequencing costs [3]